Biocon Biologics Limited, a subsidiary of Biocon Ltd. has been again recognized as an Asia IP Elite for 2023 by IAM (Intellectual Asset Management), the world's biggest IP publication.

Biocon Biologics has been awarded this accolade reserved for a select group of Asia-based corporations and research institutions that are leading the region in intellectual property value creation.

In 2019, Biocon Biologics made its debut on this prestigious list for its robust IP management and consistent IP value creation. This is the seventh consecutive year for Biocon and subsequently its subsidiary Biocon Biologics to make it to this prestigious list.

Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list. In addition, the Company's IPR team has been adjudged as the 'Healthcare and Biotechnology Team of the Year' from Asia for 2023.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said: "We are honoured to receive this prestigious award for the seventh time. This is a recognition of our commitment to innovation and creation of intellectual capital. I am very proud of our IP Team and would like to congratulate them on this remarkable achievement. Biocon Biologics remains committed to leveraging science to drive affordable innovation for the benefit of patients worldwide."

Biocon Biologics is leveraging its robust in-house IP strategy and capabilities to enable early entry of biosimilar products to meet patients' needs for affordable therapy in global markets.

This year, 88 entities from India, China, Japan, South Korea, Malaysia, Thailand, Taiwan, Australia, New Zealand, and Singapore featured on the list.